Pancreatic cancer: The RAS paradigm shift
PLOS Medicine · 29.10.2026 · 23 (10) · e1005283
DOI: 10.1371/journal.pmed.1005283 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 29.10.2026. Verfasst von Samuel P Soff und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Agents, Pancreatic Neoplasms, ras Proteins. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. Recent advances in RAS targeting with small molecules are redefining therapeutic paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
ORCID-Profile: Samuel P Soff, Eileen M O'Reilly
Zitieren
APA
Soff, S. P., & O'Reilly, E. M. (2026). Pancreatic cancer: The RAS paradigm shift. PLOS Medicine, 23(10), e1005283. https://doi.org/10.1371/journal.pmed.1005283
Vancouver
Soff SP, O'Reilly EM. Pancreatic cancer: The RAS paradigm shift. PLOS Medicine. 2026;23(10):e1005283. doi:10.1371/journal.pmed.1005283
BibTeX
@article{Soff2026,
author = {Soff, Samuel P and O'Reilly, Eileen M},
title = {Pancreatic cancer: The RAS paradigm shift},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {10},
pages = {e1005283},
doi = {10.1371/journal.pmed.1005283}
}
EUVIMED